0000358654
Donate
Active substances for the treatment of:

Malignant prostate cancer

Name of active substance (medicine) The European Society for Medical Oncology (ESMO). Published scientific research demonstrates that the observance of such scientific community guidelines has a positive impact on patient survival rates. Is it included in
the European standard  of treatment (according to ESMO)?
Access status (National Health Fund reimbursement) Additional information
Degarelix The drug in this indication is refunded in accordance with the ESMO guidelines Full reimbursement Degarelix is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer. EPAR/SmPC Drug programme
Cabazitaxel The drug in this indication is not refunded No reimbursement Cabazitaxel in combination with prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel-containing regimen. EPAR/SmPC
Abiraterone The drug in this indication is refunded in accordance with the ESMO guidelines Full reimbursement Abiraterone is indicated with prednisone or prednisolone for: - the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) - the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated - the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. EPAR/SmPC Drug programme
Enzalutamide The drug in this indication is refunded in accordance with the ESMO guidelines Full reimbursement Enzalutamide is indicated for: • the treatment of adult men with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated • the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy. EPAR/SmPC Drug programme
Radium ra223 dichloride The drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelines Reimbursement with restrictions Radium Ra223 dichloride monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment. EPAR/SmPC Drug programme
Padeliporfin The drug in this indication is not refunded No reimbursement Padeliporfin is indicated as monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy ≥ 10 years and: - Clinical stage T1c or T2a, - Gleason Score ≤ 6, based on high-resolution biopsy strategies, - PSA ≤ 10 ng/mL, - 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ≥ 50 % cancer involvement in any one core or a PSA density ≥ 0.15 ng/mL/cm3. EPAR/SmPC
Apalutamide The drug in this indication is not refunded No reimbursement Apalutamide is indicated in adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of developing metastatic disease. EPAR/SmPC